MindMed Soars on FDA Breakthrough Therapy Designation for “Truly Remarkable” Anxiety Candidate, Announces Capital Raise
    MindMed Soars on FDA Breakthrough Therapy Designation for “Truly Remarkable” Anxiety Candidate, Announces Capital Raise
    PRISM Biotech

    March 08, 2024 - by Catie Corcoran

    MindMed Soars on FDA Breakthrough Therapy Designation for “Truly Remarkable” Anxiety Candidate, Announces Capital Raise

    08 March 2024

    New York, March 08, 2024 - PRISM MarketView - Mind Medicine Inc. (Nasdaq: MNMD) has been granted FDA Breakthrough Therapy Designation for its generalized anxiety disorder (GAD) treatment candidate, MM120 (lysergide d-tartrate). MindMed also announced this week that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity.
    Mind Medicine (MindMed) Inc. - Prism MarketView

    Mind Medicine (MindMed) Inc. - Prism MarketView

    MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addictio

    Read More

    MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder - Prism MarketView

    -A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo...

    Read More

    The company’s share price soared almost 85% during Thursday’s trading session, before settling up 51.52% at the closing bell. The company gained a further 5.56% aftermarket.

    “I’ve conducted clinical research studies in psychiatry for over two decades and have seen studies of many drugs under development for the treatment of anxiety. That MM120 exhibited rapid and robust efficacy, solidly sustained for 12 weeks after a single dose, is truly remarkable.”

    David Feifel, MD, PhD, Professor Emeritus of Psychiatry at the University of California, San Diego and Director of the Kadima Neuropsychiatry Institute in La Jolla, California and an investigator in the MM120

    MindMed plans to hold an End-of-Phase 2 meeting with the FDA in the first half of 2024 and initiate a Phase 3 clinical program in the second half of 2024.
    Capital Raise
    MindMed announced the pricing of an underwritten offering of 16,666,667 common shares at an offering price of $6.00 per common share. In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.

    Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement - Prism MarketView

    NEW YORK, March 07, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

    Read More

    MindMed’s market cap stands at $372 million and 37.9 million shares changed hands during intraday trading on Thursday. The company’s average volume is 796,891 shares.
    About MindMed
    MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.
    Mind Medicine Inc. is featured on PRISM Emerging Psychedelics Index
    Psy.png

    Psychedelic Stocks ETF | List of Psychedelic Stocks

    The PRISM Psychedelics Index tracks small and micro-cap stocks that are developing or marketing legal psychedelic-derived products.

    Read More

    To see this content properly accept cookies.
    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    PRISM MarketView - Social Media (X)
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    Related Stories
    PRISM Biotech
    Quoin Pharmaceuticals Cements Leadership Position in Rare Diseases with New Research Agreement

    New York, June 13, 2024 - PRISM MarketView - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a specialty pharmaceutical company focused on rare and orphan diseases, announced a research agreement with The School of Pharmacy at University College Cork (UCC) in Ireland. This co...

    13 June 2024

    PRISM Biotech
    SS Innovations Secures Regulatory Approval in Indonesia for Flagship Surgical Robotic System

    New York, June 12, 2024 - PRISM MarketView - Leading developer of innovative surgical robotic technologies, SS Innovations International (OTC: SSII) has secured regulatory approval from the Indonesian Ministry of Health for clinical use for the use of its flagship surgic...

    12 June 2024

    PRISM Biotech
    Capricor Therapeutics Advances Treatment for Duchenne Muscular Dystrophy

    New York, June 12, 2024 - PRISM MarketView - Shares in biotechnology company Capricor Therapeutics (Nasdaq: CAPR), rose on Tuesday after the company announced that it had successfully completed a Type-B meeting with the FDA regarding a Biologics License Application (BLA)...

    12 June 2024

    PRISM Biotech
    PRISM MarketView Highlights Soligenix’s Promising HyBryte™ Replication Trial: Setting the Stage for Success

    New York, June 4, 2024 - PRISM MarketView - The late-stage biopharmaceutical company, Soligenix, Inc. (Nasdaq: SNGX), is working to address a critical gap in treatment of rare and chronic cancer, cutaneous T-cell lymphoma (CTCL). CTCL is a cancer of the white blood cells...

    4 June 2024

    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.